Arcturus Therapeutics Holdings Inc. (ARCT)
After hours:
| Previous Close | 26.98 |
| Open | 28.20 |
| Bid | 26.11 x 200 |
| Ask | 26.21 x 200 |
| Day's Range | 25.41 - 26.80 |
| 52 Week Range | 17.52 - 43.81 |
| Volume | |
| Avg. Volume | 488,103 |
| Market Cap | 704.371M |
| Beta (5Y Monthly) | 2.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.12 |
| Earnings Date | May 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 67.63 |
Business WireArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
SAN DIEGO, April 25, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2024 after the market close on Wednesday, May 8 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 8, 2024.
GuruFocus.comArcturus Therapeutics Holdings Inc (ARCT) Insider Sells Shares
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a biotechnology company focused on the discovery, development, and commercialization of RNA therapeutics for rare diseases and vaccines, has reported an insider transaction.
GuruFocus.comArcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ...
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a biotechnology company focused on the discovery, development, and commercialization of RNA therapeutics for rare diseases and vaccines, has reported an insider sale according to a recent SEC filing.
